Last updated: February 16, 2026
Product Overview
NDC 51407-0754 corresponds to Nivolumab (Opdivo) 240 mg, a PD-1 immune checkpoint inhibitor indicated for multiple cancers, including non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma. The drug is FDA-approved for various oncology indications and has received expanded indications since its initial approval.
Market Size and Demand Dynamics
The oncology market for nivolumab exhibits steady growth driven by expanding indications and increasing adoption.
- Global market size for immune checkpoint inhibitors was valued at approximately USD 20 billion in 2022.
- Nivolumab represented roughly USD 8 billion of that segment, capturing about 40% of the market share among PD-1 inhibitors as of 2022 (source: Clarivate Analytics).
- The drug's use spans over 100 countries, with primary markets in the US, EU, and Japan.
Competitor Landscape
Key competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo).
- Pembrolizumab holds the largest share, especially in NSCLC, with a peak market value exceeding USD 10 billion in 2022.
- Nivolumab's second position varies by indication, with notable strength in melanoma and renal cell carcinoma.
Pricing and Reimbursement Context
Current US wholesale acquisition cost (WAC) for nivolumab 240 mg is approximately USD 7,000 per dose.
- PBS (Public Health System) and private insurance coverage influence net prices, with negotiated discounts potentially reducing effective prices by 20-30%.
- Average sales prices (ASP) in the US hover around USD 1,400 per mg, translating to about USD 336,000 per 240 mg dose.
In Europe and Japan, prices are adjusted based on local pricing policies, often resulting in lower per-dose costs.
Regulatory and Policy Factors
- The FDA has approved nivolumab in combination therapy with other agents, expanding indications and potential patient population.
- Pricing negotiations and approval pathways differ significantly across regions, impacting global revenue streams.
- Patent protections remain valid until early-to-mid 2030s, supporting revenue streams in the near to medium term.
Price Projection Outlook
| Year |
Estimated Global Market Value (USD Billions) |
Key Drivers |
Price Trends |
| 2023 |
9.5 |
Continued adoption, new indications |
Stable to slight increase (2-4%) in US prices |
| 2024 |
10.2 |
Expanded approvals, post-pandemic recovery |
Potential marginal increase (3-5%) |
| 2025 |
11.0 |
Entry into emerging markets, biosimilars |
Prices face pressure; net increase constrained (1-3%) |
| 2026 |
12.0 |
Biosimilar market entries, patent expirations near |
Slight decrease in list prices, offset by volume growth |
| 2027 |
13.0 |
Market saturation, increased biosimilar competition |
Prices decline 10-15%, but volume increases maintain revenue growth |
Biosimilar Impact
- Biosimilars for nivolumab are pending regulatory approval in key markets.
- The first biosimilar is expected to launch in the EU by 2025, with US approval possibly around 2027.
- Biosimilar pricing may reduce list prices by 30-50% and prompt volume growth, especially in cost-sensitive markets.
Risks and Uncertainties
- Regulatory delays or additional indications could alter the revenue trajectory.
- Price erosion from biosimilar competition impacts margins.
- Changes in healthcare policy and reimbursement frameworks could influence net pricing.
Key Takeaways
- Nivolumab 240 mg remains a leading PD-1 inhibitor, underpinning a multibillion-dollar oncology franchise.
- The global market is expanding, driven by new indications and geographic penetration, but faces pricing pressures.
- The presence of biosimilars starting from 2025-2027 will introduce downward price pressure but could also expand the patient base.
- Near-term revenue growth hinges on continued adoption, indication expansion, and regional market dynamics.
FAQs
1. How will biosimilar entries affect nivolumab’s price and market share?
Biosimilars are expected to reduce list prices by up to 50%, leading to decreased revenue per unit. However, increased volume adoption could offset gross declines, especially in emerging markets.
2. What are the primary indications for NDC 51407-0754?
Nivolumab is approved for melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, and other cancers, with ongoing trials for additional uses.
3. How do regional differences impact pricing?
The US sees higher list prices (~USD 7,000 per 240 mg dose), whereas Europe and Japan tend to negotiate lower prices. Reimbursement frameworks heavily influence net prices across regions.
4. What is the expected timeline for biosimilar market entry?
EU biosimilars are expected in 2025, with US biosimilars possibly entering by 2027, subject to regulatory approvals and market conditions.
5. How might future regulatory changes affect market prospects?
Potential indications, combination approvals, or reimbursement reforms could significantly influence market size and pricing strategies.
References
[1] Clarivate Analytics. "Global Oncology Market Report, 2022."
[2] FDA Drug Database, 2023.
[3] IQVIA. "Pharmaceutical Pricing & Market Access Data, 2022."
[4] European Medicines Agency. "Biosimilar Approvals and Forecasts," 2023.
[5] Company Annual Reports and Market Announcements, 2022–2023.
